A Phase Ib, Multicentre, Randomised, Single-blind, Parallel-group, Placebo-controlled, Study to Characterise the Pharmacokinetics and Pharmacodynamics of AZD4604 Administered via the Turbuhaler® Device in Adults with Mild Asthma

2024-516474-30-00 Protocol D8210C00006 Human pharmacology (Phase I) - Other Ended

Start 19 Feb 2025 · End 29 May 2025 · Status Ended · 1 EU/EEA countries · 6 sites · Protocol D8210C00006

Overview

Sponsor-declared trial summary

Phase Human pharmacology (Phase I) - Other
Status Ended
Participants planned 28
Countries 1
Sites 6

Asthma

Key facts

Sponsor
AstraZeneca AB
Participant type
Patients
Age range
18-64 years
Gender
Male and Female
Therapeutic area
Diseases [C] - Respiratory Tract Diseases [C08]
Trial duration
19 Feb 2025 → 29 May 2025
Decision date (initial)
2024-11-21
Transition trial
No
Low-intervention
No
Rare-disease indication
No
Vulnerable population
Yes

Trial design

CTIS Part I — objectives, methods, condition coding

Conditions and MedDRA coding

Asthma

VersionLevelCodeTermSystem organ class
20.0 PT 10003553 Asthma 100000004855

Sponsors and contacts

Sponsor organisations, regulatory contacts, third parties

AstraZeneca AB

Sponsor organisation
AstraZeneca AB
Address
-
City
Sodertalje
Postcode
151 85
Country
Sweden

Scientific contact point

Organisation
AstraZeneca AB
Contact name
Clinical Study Information Centre

Public contact point

Organisation
AstraZeneca AB
Contact name
Clinical Study Information Centre

Locations

1 EU/EEA country · 6 investigational sites

By country

CountryMS statusPlanned subjectsSites
Germany Ended 16 6
Rest of world
United Kingdom
12

Investigational sites

Germany

6 sites · Ended
Velocity Clinical Research GmBH
#2606, Ansbacher Strasse 17-19, Schoeneberg, Berlin
IKF Pneumologie GmbH & Co. KG
#2604, Stresemannallee 3, Sachsenhausen, Frankfurt Am Main
The Fraunhofer Institute For Toxicology And Experimental Medicine ITEM
#2605:Clinical Airway Research, Nikolai-Fuchs-Strasse 1, Gross Buchholz, Hanover
Studienpraxis Berlin-Brandenburg Cornelia Seelbinder Und Lennart Schaper GbR
#2603, Torstrasse 117, Mitte, Berlin
Velocity Clinical Research Germany GmbH
#2601, Sandstrasse 18, Innenstadt, Luebeck
Velocity Clinical Research Germany GmbH
#2602, Klaus-Groth-Strasse 2-4, 22926, Ahrensburg

Country notifications

Trial-start, recruitment-start, end and early-termination notifications submitted per Member State

Country Trial startTrial end Recruitment startRecruitment end Early termination
Germany 2025-02-19 2025-05-09 2025-03-10 2025-03-25

Application history

1 submissions — initial application plus substantial / non-substantial modifications

#TypeCodeSubmittedReference MSConclusionDecision date
1 INITIAL IN 2024-09-27 Germany Acceptable
2024-11-05
2024-11-21